Le Lézard
Classified in: Health
Subject: PLW

FastWave Medical Announces IVL Utility Patent Granted From USPTO to Treat Cardiovascular Calcium

FastWave Medical received an allowance of the patent within just six months of filing, demonstrating the company's ability to quickly execute in the multi-billion dollar intravascular lithotripsy (IVL) market.

MINNEAPOLIS, Feb. 1, 2023 /PRNewswire-PRWeb/ -- FastWave Medical, a privately held company incubated by partners of Big Sky Biomedical, announced today it has been awarded a utility patent from the USPTO. FastWave Medical is rapidly developing intravascular lithotripsy (IVL) systems that are procedurally-efficient and cost-effective. The company is poised to disrupt this $9 billion addressable market with a novel solution for peripheral and coronary artery calcification (CAC).

"I am beyond thrilled that our fast-moving team has achieved this significant milestone. Receiving a non-provisional utility patent, with broad claim sets, for our novel IVL system in just six months is truly impressive," said Scott Nelson, Chief Executive Officer and Co-Founder of FastWave Medical. "Cardiovascular calcium is complex to treat and there is a significant need for new interventional procedures; our system increases procedural efficiency and provides a more user-friendly experience to address this multi-billion dollar market."

CAC is present in 90% of men and 67% of women older than the age of 70. While there have been advancements in CAC therapeutic options over the last few decades, global cardiovascular disease is on the rise and there remains an unmet need for improved technologies to treat calcific arterial plaque. Existing interventions can be costly and cumbersome to use, and many procedures come with an increased risk of adverse events. FastWave's IVL systems are minimally-invasive and improve upon current offerings through enhanced catheter crossability, upgraded durability, and overall ease of use.

"Our incredible team has deep interventional vascular expertise, which has allowed us to achieve milestones with exceptional speed. A non-provisional utility patent granted this fast is virtually unheard of in the medical device industry," said Tristan Tieso, Chief Operating Officer of FastWave Medical. "Our IVL systems offer clear differentiation versus other devices on the market and I couldn't be more proud of the progress our strong group of engineers and technicians have made over the last year."

About FastWave Medical Inc.
FastWave Medical, a privately held company incubated by partners of Big Sky Biomedical, is focused on developing intravascular lithotripsy (IVL) systems for calcific artery disease that are procedurally efficient and cost-effective. To learn more about FastWave Medical, please visit https://fastwavemedical.com.

About Big Sky Biomedical, LLC
Founded by a group of medical device serial entrepreneurs with extensive expertise in the vascular space, Big Sky Biomedical is a highly specialized accelerator focused on rapid, capital-efficient therapy development. To learn more about Big Sky Biomedical, please visit https://bigskybiomedical.com.

Media Contact
[email protected]

Media Contact

Media Contact, FastWave Medical, 1 (833) 888-9283, [email protected]


SOURCE FastWave Medical

These press releases may also interest you

at 07:25
United Network for Organ Sharing (UNOS) has rolled out a new organ allocation system designed to be more equitable and effective for patients in need of lung transplants....

at 07:14
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights Clinical developmentSTP705-  The part-one Phase IIb interim data on STP705 for the...

at 07:10
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). The interest-only secured credit...

at 07:10
ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheiatm A1002N5S, an investigational drug using cannabidiol...

at 07:10
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the...

at 07:09
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its...

News published on 1 february 2023 at 09:05 and distributed by: